ATE467124T1 - Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung - Google Patents

Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Info

Publication number
ATE467124T1
ATE467124T1 AT03754894T AT03754894T ATE467124T1 AT E467124 T1 ATE467124 T1 AT E467124T1 AT 03754894 T AT03754894 T AT 03754894T AT 03754894 T AT03754894 T AT 03754894T AT E467124 T1 ATE467124 T1 AT E467124T1
Authority
AT
Austria
Prior art keywords
prp
molecules interacting
sup
peptides
features
Prior art date
Application number
AT03754894T
Other languages
German (de)
English (en)
Inventor
Neil Cashman
Eustache Paramithiotis
Boissiere Sylvie La
Robert Lawton
Greg Francoeur
Lisa Estey
Marc Pinard
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Application granted granted Critical
Publication of ATE467124T1 publication Critical patent/ATE467124T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03754894T 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung ATE467124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,538 US20040072236A1 (en) 2002-09-27 2002-09-27 PrPSc -interacting molecules and uses thereof
PCT/US2003/030273 WO2004029072A2 (en) 2002-09-27 2003-09-25 PrPsc -INTERACTING MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE467124T1 true ATE467124T1 (de) 2010-05-15

Family

ID=32041771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754894T ATE467124T1 (de) 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Country Status (7)

Country Link
US (2) US20040072236A1 (show.php)
EP (1) EP1575989B1 (show.php)
JP (1) JP4533750B2 (show.php)
AT (1) ATE467124T1 (show.php)
CA (1) CA2500120A1 (show.php)
DE (1) DE60332488D1 (show.php)
WO (1) WO2004029072A2 (show.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
JP4235544B2 (ja) 2001-05-31 2009-03-11 アドライフ インコーポレーティッド 欠陥折畳み蛋白質センサー方法
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
EP1616036A4 (en) * 2003-04-14 2007-03-21 Pathogen Removal And Diagnosti PROCESS FOR IDENTIFYING LIGANDS SPECIFIC TO STRUCTURAL FORMS OF PROTEINS
US7439041B2 (en) 2003-08-13 2008-10-21 Novartis Vaccines And Diagnostics, Inc. Prion-specific peptide reagents
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7328063B2 (en) * 2004-11-30 2008-02-05 Cardiac Pacemakers, Inc. Method and apparatus for arrhythmia classification using atrial signal mapping
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP1848831A4 (en) * 2005-01-13 2008-11-05 Novartis Vaccines & Diagnostic ELISA TESTS USING PRION-SPECIFIC PEPTIDE REAGENT
EP1853915B1 (en) * 2005-02-15 2011-10-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2007030804A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Prion-specific peptoid reagents
JP4769925B2 (ja) * 2006-03-15 2011-09-07 国立大学法人東北大学 異常型プリオン蛋白質の濃縮方法、および除去方法
BRPI0714930A2 (pt) * 2006-07-28 2013-05-21 Adlyfe Inc sondas peptÍdicas para fins diagnàsticos e terapÊuticos
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
WO2008083972A2 (en) * 2007-01-12 2008-07-17 Alicon Ag Method for removing prion protein
US9056918B2 (en) * 2008-04-25 2015-06-16 University Of Saskatchewan Prion epitopes and methods of use thereof
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
US20120009209A1 (en) * 2010-06-10 2012-01-12 The Regents Of The University Of California Enrichment and purification of infectious prion proteins
WO2012037095A1 (en) * 2010-09-13 2012-03-22 Abbott Laboratories A highly sensitive monoclonal antibody residual detection assay

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0647849A3 (en) 1986-04-30 1996-05-15 Igen Inc Detection of the presence of analytes in a sample.
SU1529119A1 (ru) 1987-04-20 1989-12-15 Белорусский научно-исследовательский институт эпидемиологии и микробиологии Способ определени нейровирусов в спинномозговой жидкости
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
AU9028791A (en) 1990-10-05 1992-04-28 President And Fellows Of Harvard College Detection and isolation of ligands
EP0619841B1 (en) 1990-10-30 1998-07-08 La Jolla Cancer Research Foundation T-cadherin adhesion molecule
US5773572A (en) * 1991-12-03 1998-06-30 Proteus Molecular Design Limited Fragments of prion proteins
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
EP0604603A4 (en) * 1992-04-17 1996-09-25 Doheny Eye Inst ELEMENTS AND METHODS FOR THE PRODUCTION OF CADHERINES.
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5643781A (en) * 1992-12-29 1997-07-01 Doheny Eye Institute DNA encoding protocadherin-42
US5798224A (en) 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
US5679530A (en) 1995-04-12 1997-10-21 Ludwig Institute For Cancer Research Isolated protein having molecular weight of from about 55 kilodaltons to about 65 kilodaltons (SDS-page) which binds to prion protein
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
AU707484B2 (en) 1995-09-14 1999-07-08 Regents Of The University Of California, The Antibodies specific for native PrPsc
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
US6451541B1 (en) * 1996-05-14 2002-09-17 Ernst-Ludwig Winnacker Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc
WO1997045746A2 (en) * 1996-05-29 1997-12-04 Mcgill University Prion protein binding proteins and uses thereof
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
DE1057022T1 (de) 1998-02-20 2001-10-25 The Regents Of The University Of California, Oakland Assay für spezifische stämme von mit mehreren krankheiten zusammenhängenden proteinkonformationen
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
JP2003521477A (ja) * 1999-06-23 2003-07-15 カプリオン ファーマシューティカルズ インコーポレーティッド プリオン蛋白質ペプチドおよびその使用
CA2376914A1 (en) * 1999-06-29 2001-01-04 Mcgill University Prion protein binding proteins and uses thereof
EP1272509A2 (en) * 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof

Also Published As

Publication number Publication date
US7435540B2 (en) 2008-10-14
DE60332488D1 (de) 2010-06-17
WO2004029072A3 (en) 2005-12-15
JP4533750B2 (ja) 2010-09-01
JP2006507484A (ja) 2006-03-02
CA2500120A1 (en) 2004-04-08
US20040072236A1 (en) 2004-04-15
WO2004029072A2 (en) 2004-04-08
EP1575989A2 (en) 2005-09-21
EP1575989A4 (en) 2007-05-16
EP1575989B1 (en) 2010-05-05
AU2003272695A1 (en) 2004-04-19
US20060183156A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE467124T1 (de) Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
EP1480657A4 (en) POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I
EP1912674A4 (en) BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE382053T1 (de) System zur antikörperexpression und- synthese
CY1116256T1 (el) Il-17 ανταγωνιστικα αντισωματα
ATE424560T1 (de) Marker für neuromyelitis optica
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
BR0014626A (pt) Análise de leptina
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties